Your AI-Trained Oncology Knowledge Connection!
Evolving Practices for Myelodysplastic Syndromes (MDS): Highlights from ASH 2024 and Beyond : Episode 5
Opinion
Video
Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS
Author(s):
Panelists discuss how oral decitabine/cedazuridine showed encouraging efficacy in patients with myelodysplastic syndromes (MDS) with TP53 mutations, suggesting this oral formulation could be particularly beneficial for this historically difficult-to-treat molecular subgroup.
Video content above is prompted by the following:
• Can you share any key takeaways or additional data updates surrounding MDS presented at ASH 2024?
• Oral decitabine/cedazuridine in MDS and TP53 mutations.
Related Videos
Related Content
